Michael A. Mussallem - 05 Feb 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Director
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
05 Feb 2024
Net transactions value
-$1,489,141
Form type
4
Filing time
05 Feb 2024, 18:37:44 UTC
Previous filing
05 Jan 2024
Next filing
04 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $1,078,612 +29,350 +654% $36.75 33,836 05 Feb 2024 Direct F1
transaction EW Common Stock Sale $89,610 -1,000 -3% $89.61 32,836 05 Feb 2024 Direct F1, F2
transaction EW Common Stock Sale $569,182 -6,422 -20% $88.63 26,414 05 Feb 2024 Direct F1, F3
transaction EW Common Stock Sale $843,741 -9,761 -37% $86.44 16,653 05 Feb 2024 Direct F1, F4
transaction EW Common Stock Sale $1,065,221 -12,167 -73% $87.55 4,486 05 Feb 2024 Direct F1, F5
holding EW Common Stock 4,038,377 05 Feb 2024 By Living Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -29,350 -25% $0.000000 88,050 05 Feb 2024 Common Stock 29,350 $36.75 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $89.390 to $90.080. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $88.210 to $89.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $86.100 to $87.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $87.110 to $88.105. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.